# Phase 2 Nasopharyngeal Carcinoma trials: 63 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 63 trials in phase 2 for Nasopharyngeal Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Nasopharyngeal Carcinoma trials: 63 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/nasopharyngeal-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 63
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07902713 | Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902713) |
| September 17, 2026 | NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases, Oligometastatic Disease, Ablation... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824856) |
| September 1, 2026 | NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797881) |
| August 27, 2026 | NCT07789158 | Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma | Fudan University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789158) |
| August 24, 2026 | NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781358) |
| August 13, 2026 | NCT07762976 | Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma | Fudan University | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762976) |
| August 10, 2026 | NCT07756190 | Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756190) |
| May 12, 2026 | NCT07581821 | Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581821) |
| May 5, 2026 | NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Recruiting | Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC) | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567742) |
| May 4, 2026 | NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | National University Hospital, Singapore | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565389) |
| April 29, 2026 | NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555860) |
| February 5, 2026 | NCT07388758 | Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388758) |
| January 23, 2026 | NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Recruiting | Nasopharyngeal Cancinoma (NPC) | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362979) |
| January 9, 2026 | NCT07331428 | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC | Fujian Cancer Hospital | Phase 2 | Recruiting | Nasopharyngeal Carcinoma, Local Recurrence | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331428) |
| January 8, 2026 | NCT07325539 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC | Sun Yat-sen University | Phase 2 | Recruiting | Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325539) |
| December 24, 2025 | NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303283) |
| December 11, 2025 | NCT07277764 | Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm... | Jiangxi Provincial Cancer Hospital | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277764) |
| November 26, 2025 | NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal... | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252375) |
| August 24, 2025 | NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Cancinoma (NPC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138989) |
| August 22, 2025 | NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | Affiliated Hospital of Guangdong Medical University | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136519) |
| August 19, 2025 | NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | The University of Hong Kong | Phase 2 | Not yet recruiting | Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC) | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129772) |
| August 7, 2025 | NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Cancinoma (NPC) | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110558) |
| August 3, 2025 | NCT07101744 | Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm... | Sun Yat-sen University | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101744) |
| July 25, 2025 | NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | Jiangxi Provincial Cancer Hospital | Phase 2 | Recruiting | Nasopharyngeal Carcinoma (NPC) | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085988) |
| July 17, 2025 | NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | Sponsor not shown (see the record) | Phase 2 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070479) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 23 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| Fujian Cancer Hospital | 3 |
| Fudan University | 3 |
| National Cancer Institute (NCI) | 3 |
| National University Hospital, Singapore | 2 |
| Jiangxi Provincial Cancer Hospital | 2 |
| NRG Oncology | 1 |
| Zhejiang Cancer Hospital | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| The University of Hong Kong | 1 |
| First Affiliated Hospital of Guangxi Medical University | 1 |
| Taizhou Hospital | 1 |
| Stanford University | 1 |
| National Cancer Centre, Singapore | 1 |
| Sichuan Cancer Hospital and Research Institute | 1 |
| Chongqing University Cancer Hospital | 1 |
| Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 1 |
| RenJi Hospital | 1 |
| Hunan Cancer Hospital | 1 |
| Emory University | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Affiliated Hospital of Guangdong Medical University | 1 |
| Xinqiao Hospital of Chongqing | 1 |
| German Society for Pediatric Oncology and Hematology GPOH gGmbH | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 46 |
| United States | 6 |
| Singapore | 4 |
| Hong Kong | 2 |
| Australia | 2 |
| Canada | 2 |
| Germany | 1 |
| New Zealand | 1 |
| Puerto Rico | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Dumpling restaurants in the United States](https://specstream.ai/data/businesses/dumpling-restaurants/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
